CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma; Recurrent Multiple Myeloma; Refractory Multiple Myeloma
Interventions: Procedure: Leukapheresis; Drug: Cyclophosphamide; Biological: Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA; Behavioral: Quality of Life (QoL) Questionnaires; Procedure: Bone Marrow Biopsy; Biological: Biospecimen Collection; Drug: Fludarabine; Procedure: Radiographic imaging
Sponsors: Thomas Martin, MD
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 15, 2026Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | ClinicalTrials.gov | Drug Trials Near Me | US National Library of Medicine
Comments